<DOC>
	<DOCNO>NCT01609218</DOCNO>
	<brief_summary>The study evaluate effect activate charcoal absorption LY2140023 . The study involve single dose 80 milligram ( mg ) LY2140023 take 1 tablet mouth two time study ( activated charcoal , without activated charcoal ) . This study last approximately 16 day include screening . Screening require within 30 day prior study entry .</brief_summary>
	<brief_title>A Study LY2140023 Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Charcoal</mesh_term>
	<criteria>healthy male female , determine medical history physical examination male participant agree use reliable method birth control study 3 month follow last dose LY2140023 , agree donate sperm 3 month follow last dose LY2140023 female participant : childbearing potential , test negative pregnancy screen agree use reliable method birth control study 3 month follow last dose LY2140023 nonchildbearing potential ; postmenopausal permanently sterile follow hysterectomy , bilateral salpingectomy confirm tubal occlusion ( tubal ligation ) . Postmenopausal define spontaneous amenorrhea least 12 month , plasma folliclestimulating hormone ( FSH ) level &gt; 40 milliinternational unit per milliliter ( mIU/mL ) , unless participant take hormone replacement therapy â€¢ give write informed consent approve Lilly choose ethical review board ( ERB ) currently enrol , complete discontinue within last 90 day , clinical trial involve investigational product investigational product use study ; concurrently enrol type medical research judge scientifically medically compatible study know allergy LY2140023 LY404039 , related compound , activate charcoal , component formulation participant previously withdraw study study investigate LY2140023 receive least 1 dose LY2140023 show evidence history significant active neuropsychiatric disease ( example , manic depressive illness , schizophrenia , depression ) increase risk seizure base history : one seizure ( except single simple febrile seizure [ lack focality last less 15 minute , associated central nervous system ( CNS ) infection severe metabolic disturbance ] child age 6 month 5 year ) head trauma loss consciousness postconcussive syndrome within 1 year lifetime history head trauma persistent neurological deficit ( focal diffuse ) CNS infection , uncontrolled migraine transient ischemic attack ( TIA ) within 1 year ; stroke persistent neurological deficit ( focal diffuse ) , uncontrolled migraine define migraine attack produce headache last 72 hour often accompany associate symptom ( nausea , photophobia , phonophobia ) impair wellbeing disrupt social functioning . TIA define `` ministroke '' cause temporary disturbance blood supply area brain , result sudden , brief decrease brain function CNS infection persistent neurological deficit ( focal diffuse ) brain surgery electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity ( isolated spike wave , repetitive burst sharp wave , paroxysmal activity , frank seizure , spikewave complex , sharpslow wave complex , locally define ) brain structural lesion , include developmental abnormality , determine examination image study ( except hydrocephalus treat shunt without neurological deficit ) show evidence active renal disease ( example , diabetic renal disease , polycystic kidney disease ) creatinine clearance le 90 milliliter per minute ( mL/min ) determine Cockroft Gault formula show evidence history know substance dependence abuse time ( accord Diagnostic Statistical Manual Mental Disorders [ DSMIV ] diagnosis ) , regularly use know drug abuse and/or show positive finding urinary drug screen clinically significant abnormality neurological examination participant judge prior randomization suicidal risk investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>